There is no specific timeline for administering the MMR (measles, mumps, and rubella) vaccine after receiving Cosentyx (secukinumab). Cosentyx is a medication used to treat several conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, while the MMR vaccine is a childhood immunization.
The Centers for Disease Control and Prevention (CDC) recommends that children receive the MMR vaccine between 12 and 15 months of age, with a second dose between 4 and 6 years of age. However, the CDC does not provide specific guidance on the timing of the MMR vaccine in relation to Cosentyx or other medications.
Cosentyx is a biologic medication that works by targeting a specific protein in the immune system. Like other biologic medications, Cosentyx can increase the risk of infection, so it is important to stay up-to-date on recommended vaccinations. However, the CDC recommends that live vaccines, such as the MMR vaccine, be given at least 4 weeks before starting Cosentyx or at least 12 weeks after the last dose of Cosentyx.
It is important to consult with a healthcare provider to determine the best timing for vaccinations based on individual medical history and current medications.
Sources:
* Centers for Disease Control and Prevention. (2021). Measles, Mumps, and Rubella (MMR) Vaccine. <https://www.cdc.gov/vaccines/vpd/mmr/public/index.html>.
* Cosentyx (secukinumab) [prescribing information]. (2021). Novartis Pharmaceuticals Corporation. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>.
* DrugPatentWatch. (2021). Cosentyx (secukinumab) Drug Profile. <https://www.drugpatentwatch.com/drugs/cosentyx>.